Public Meeting to Discuss Increasing the Use of Naloxone to Reduce the Incidence of Opioid Drug Overdose Fatalities
Start Date: July 01, 2015
End Date: July 02, 2015
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research, in collaboration with the National Institutes on Drug Abuse, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, will hold a public meeting to discuss increasing the use of naloxone to reduce the incidence of opioid drug overdose fatalities. During the meeting, academic and government experts, industry representatives, and patient advocates will discuss which populations are at-risk for opioid drug overdose and how we can work together to encourage the use of naloxone to reduce the risk of overdose from opioid drugs.
Date and Time: The public meeting will be held on July 1, 2015, from 8 a.m. to 5 p.m. and on July 2, 2015, from 8 a.m. to 3 p.m. The open public hearing will be held between 1 p.m. and 2 p.m. on July 1, 2015, and between 1 p.m. and 2 p.m. on July 2, 2015, during which speaker testimony will be accepted.
Location: For those wishing to attend in person, the public meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-0002.
Webcast information will be posted a few days prior to the meeting – please check the meeting webpage for updates.
Registration: If you wish to attend the public meeting or provide testimony during the open public hearing, please email your registration to NaloxoneWorkshop@fda.hhs.gov by June 22, 2015.
For more information see the Federal Register Notice: https://www.federalregister.gov/articles/2015/05/19/2015-12061/exploring-naloxone-uptake-and-use-public-meeting-request-for-comments
The SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) does not endorse or attest to the quality of the content. Questions regarding content, recordings, and additional information should be directed to the host organization and/or presenter.
More Info Url: